Monday, November 21, 2011

Exelixis' cabo targets breast cancer in mid-stage trial

A mid-stage trial of Exelixis Inc.’s experimental drug cabozantinib in women with breast cancer that has spread to the bone has started at the Massachusetts General Hospital Cancer Center.
South San Francisco-based Exelixis (NASDAQ: EXEL) said the main point of the 50-patient trial is to see if cabozantinib has an affect on the bone cancers. Women will receive the drug once a day and be evaluated every 12 weeks until the drug’s toxicity proves unacceptable or the cancer progresses.

No comments:

Post a Comment